Pivot Pharma Wraps Up a Successful 2017
Ryan Allway
December 28th, 2017
Exclusive, News, Top News
The North American cannabis industry reached $6.7 billion in 2016, according to ArcView Research, which represented a healthy 30% growth rate over the prior year. Over the next three years, the analyst firm expects the industry to grow at a 25% compound annual growth rate to reach $20.2 billion in sales. One company, Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF), successfully completed an about-face in 2017 to focus exclusively on the explosive sector. In this article, we will review the company’s achievements and how its business model aligns with trends in the industry.
New Focus on Cannabis
Pivot Pharmaceuticals first announcement related to cannabis came on September 12, 2017. The company acquired worldwide rights and a patent for the proprietary BiPhasix™ Transdermal Drug Delivery technology, for the development of cannabis-related products. The technology has been shown to significantly enhance the bioavailability of drugs by transporting them effectively through the skin, and the drugs delivered in this manner can target peripheral areas of the body to deliver a payload through the skin without damaging the organ from repeated application.
The acquisition was intended to address cannabinoid delivery which is an overarching problem throughout the industry. Smoking is not necessarily a preferred delivery mechanism due mostly to side effects and health concerns, and ingestion is ineffective due to metabolic effects of the liver as well as inherent problems with the absorption of cannabinoids due to insolubility in water. So Pivot Pharma’s first move was to acquire a proven technology and focus it on cannabis. But the company was by no means done.
Pivot announced two weeks later the acquisition of worldwide rights to Solmic Research GmbH’s Solmic Solubilisation Technology. This is an oral delivery technology that makes cannabinoids water-soluble and protects them from degradation due to stomach acids and enzymes. The technology masks unpleasant odour and taste and improves stability of the mixture. Pivot is advancing several Natural Health Products as a result of this technology, including products intended for opioid addicts and cancer patients.
A few weeks later, in early November, Pivot entered into a binding agreement to acquire a third delivery technology, Thrudermic’s Transdermal Nanotechnology. This new technology allows Pivot to control and prolong the release of cannabinoid actives while maintaining high concentrations of the drug throughout the application period. Unlike BiPhasix™, the Thrudermic technology allows for more sophisticated systemic exposure from fast uptake to slow release.
Taken together, the three delivery technologies provide a wide array of options for development and commercialization of cannabinoid-based nutraceuticals and medicines. While many companies are focused on the production and sale of cannabis flower products, there is an increasing demand for more specific and refined products utilizing extracts from the cannabis plant.
Positioning for a Big Year
With some innovative delivery technologies in place, Pivot Pharma entered into another binding agreement, this time for the acquisition of ERS Holdings, LLC. ERS has a patented technology called Ready to Infuse Cannabis (RTIC) that changes cannabis oil extracts into a tasteless powder suitable for infusion into food and beverage products. Cannabis oils suffer from the above-mentioned bioavailability issues, but also have a notorious taste problem. The RTIC technology solves both issues, and opens up a whole world of consumer product possibilities for Pivot Pharmaceuticals.
In a final move before the end of the year, the company entered into a binding agreement to establish a California-based business to accelerate the commercialization of the newly-acquired RTIC powders. With California poised to fully legalize cannabis on Jan. 1, 2018, thereby becoming the world’s largest legal cannabis market, Pivot is looking to quickly capitalize on the innovative technology.
Looking Ahead
Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) just recently started trading on the Canadian Securities Exchange, opening up the company’s stock to a whole new market of cannabis-savvy investors. Additionally, the company announced a 45-day standstill agreement that will end on February 6, 2018. In the interim, Pivot hopes to finalize a partnership with a “…best-in-class partner to monetize our patented technologies…” The agreement means that Pivot will not enter into or negotiate any other partnerships within the 45-day period. Read into this what you will, but with Canada and California both legalizing adult use of cannabis in 2018, the year ahead should be full of interesting developments for Pivot Pharmaceuticals.
For more information, visit the company’s website at www.pivotpharma.com.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures. A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
Mojave Jane Brands Inc. is a Canadian-based cannabis sector brand and distribution company emerging as a true vertical integrator in California’s legal cannabis space serving recreational and wellness markets. The Company’s U.S. holdings are comprised of assets set up as a vertical stack including cultivation to scale, branding, packaging, manufacturing & processing, as well as, […]
Amercanex was founded with the sole-purpose to ensure a completely transparent, neutral, and non-manipulated marketplace for cannabis industry participants.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
